Liquid Biopsy Market by Manufacturers, Countries, Type and Application, Forecast to 2022
According to Stratistics
MRC, the Global Liquid Biopsy market is expected to grow from $310.0 million in
2016 to reach $1201.52 million by 2023 with a CAGR of 21.3%. Increasing
research & developments and clinical trials for diagnostics, and
technological developments are some of the factors driving the market growth.
Moreover, growing prevalence of cancer, increasing awareness about liquid
biopsy are the factors fostering the market growth. On the other hand, higher
costs and complex regulations are restraining the market growth.
Liquid biopsy tests are
used to help find cancer at an early stage. These tests are performed to
interpret the molecular aspects of cancer across the healthcare and research
settings, such as research laboratories, physicians, pathological and
hospitals. The circulating tumor cells leads the market globally with the
largest market share and is expected to grow with a highest CAGR during the
forecast period. By cancer type, lung cancer segment is expected to witness
high growth rate during the forecast period. North America emerged as the major
revenue generating region in the global market due to innovative technological
developments, and increasing incidence of cancer rates in the Canada and
U.S.
Some of the key players in global liquid biopsy market include Roche Diagnostics, Guardant Health, Inc, Illumina, Inc, Biocept, Inc, Myriad Genetics, Inc, Qiagen N.V. , Genomic Health, Inc
Thermo Fisher Scientific Inc , Bio-Rad Laboratories, Inc, Epic Sciences, Exosome, Cynvenio
Guardant Health, Personal Genome Diagnostics and Janssen Diagnostics, LLC.
Clinical Applications Covered:
Treatment Monitoring
Recurrence Monitoring
Early Cancer Screening
Therapy Selection
Product and Services Covered:
Platforms & Instruments
Assay Kits & Reagents
Services
Some of the key players in global liquid biopsy market include Roche Diagnostics, Guardant Health, Inc, Illumina, Inc, Biocept, Inc, Myriad Genetics, Inc, Qiagen N.V. , Genomic Health, Inc
Thermo Fisher Scientific Inc , Bio-Rad Laboratories, Inc, Epic Sciences, Exosome, Cynvenio
Guardant Health, Personal Genome Diagnostics and Janssen Diagnostics, LLC.
Clinical Applications Covered:
Treatment Monitoring
Recurrence Monitoring
Early Cancer Screening
Therapy Selection
Product and Services Covered:
Platforms & Instruments
Assay Kits & Reagents
Services
Full report with Table of
Content: https://marketreportscenter.com/reports/571533/liquid-biopsy-global-market-outlook-2017-2023
Cancer Types Covered:
Breast Cancer
Liver Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Other Cancer Types
Circulating Biomarkers Covered:
Circulating Tumor DNA (CTDNA)
Extracellular Vesicles (Evs)
Circulating Tumor Cells
Cell-Free DNA
Exosomes
Other Circulating Biomarkers
Breast Cancer
Liver Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Other Cancer Types
Circulating Biomarkers Covered:
Circulating Tumor DNA (CTDNA)
Extracellular Vesicles (Evs)
Circulating Tumor Cells
Cell-Free DNA
Exosomes
Other Circulating Biomarkers
…
About
Market Reports Center;
Market Reports Center is an e-commerce platform
obliging the needs of knowledge workers, experts, professionals who are subject
to market research information for their work, or to make strategic business
decisions. We are dedicated to create a comprehensive offering of market
research which is accurate, credible and affordable.
Connect
for more details:
Sam
Collins
Market
Reports Center
1-646-883-3044
(US)
Comments
Post a Comment